Psychopharmacology of Anxiety Disorders

Serotonin is the primary neurotransmitter system implicated in anxiety disorders. Dysregulation of serotonin signaling is thought to play a significant role in the pathophysiology of these disorders.

SSRIs are commonly used as first-line treatment for GAD due to their efficacy, tolerability, and relatively low risk of dependence.

Benzodiazepines exert their anxiolytic effects by potentiating GABAergic neurotransmission, resulting in increased inhibitory activity in the central nervous system.

Drowsiness is a common side effect of benzodiazepines, particularly at higher doses or in sensitive individuals.

Buspirone exerts its anxiolytic effects primarily through partial agonism at serotonin receptors, particularly the 5-HT1A receptor.

SSRIs can interact with warfarin, increasing the risk of bleeding due to inhibition of warfarin metabolism.

Benzodiazepines are generally recommended for short-term use (2-4 weeks) in the treatment of anxiety disorders due to the risk of dependence and withdrawal symptoms.

Dry mouth is a common side effect of TCAs due to their anticholinergic properties.

Pregabalin exerts its anxiolytic effects primarily through modulation of voltage-gated calcium channels, reducing neuronal excitability.

Pregabalin can interact with alcohol, potentiating the sedative effects of both substances.

The recommended dosage range for buspirone in the treatment of anxiety disorders is typically 20-30 mg/day, divided into two or three doses.

Drowsiness is a common side effect of hydroxyzine due to its antihistaminic properties.

Propranolol exerts its anxiolytic effects primarily through blockade of beta-adrenergic receptors, reducing the sympathetic nervous system activity.

Propranolol can interact with warfarin, increasing the risk of bleeding due to inhibition of warfarin metabolism.

The recommended dosage range for propranolol in the treatment of anxiety disorders is typically 20-40 mg/day, divided into two or three doses.